These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 18979283)

  • 1. Yeast bioassay for identification of inositol depleting compounds.
    Ding D; Shi Y; Shaltiel G; Azab AN; Pullumbi E; Campbell A; Mehta DV; Agam G; Greenberg ML
    World J Biol Psychiatry; 2009; 10(4 Pt 3):893-9. PubMed ID: 18979283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rational polypharmacy in the bipolar affective disorders.
    Post RM; Ketter TA; Pazzaglia PJ; Denicoff K; George MS; Callahan A; Leverich G; Frye M
    Epilepsy Res Suppl; 1996; 11():153-80. PubMed ID: 9294735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lithium and bipolar mood disorder: the inositol-depletion hypothesis revisited.
    Harwood AJ
    Mol Psychiatry; 2005 Jan; 10(1):117-26. PubMed ID: 15558078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ethylbutyrate, a valproate-like compound, exhibits inositol-depleting effects--a potential mood-stabilizing drug.
    Azab AN; Mehta DV; Chesebro JE; Greenberg ML
    Life Sci; 2009 Jan; 84(1-2):38-44. PubMed ID: 19028504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticonvulsant efficacy of valproate-like carboxylic acids: a potential target for anti-bipolar therapy.
    Azab AN; Greenberg ML
    Bipolar Disord; 2007 May; 9(3):197-205. PubMed ID: 17430293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Valproate decreases inositol biosynthesis.
    Shaltiel G; Shamir A; Shapiro J; Ding D; Dalton E; Bialer M; Harwood AJ; Belmaker RH; Greenberg ML; Agam G
    Biol Psychiatry; 2004 Dec; 56(11):868-74. PubMed ID: 15576064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myristoylated alanine-rich C kinase substrate (MARCKS): a molecular target for the therapeutic action of mood stabilizers in the brain?
    Lenox RH; McNamara RK; Watterson JM; Watson DG
    J Clin Psychiatry; 1996; 57 Suppl 13():23-31; discussion 32-3. PubMed ID: 8970502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epi-inositol regulates expression of the yeast INO1 gene encoding inositol-1-P synthase.
    Shaldubina A; Ju S; Vaden DL; Ding D; Belmaker RH; Greenberg ML
    Mol Psychiatry; 2002; 7(2):174-80. PubMed ID: 11840310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapy of bipolar affective illnesses with valproate. A review of the literature].
    Retzow A; Emrich HM
    Psychiatr Prax; 1998 Jul; 25(4):163-71. PubMed ID: 9738242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bipolar disorder and myo-inositol: a review of the magnetic resonance spectroscopy findings.
    Silverstone PH; McGrath BM; Kim H
    Bipolar Disord; 2005 Feb; 7(1):1-10. PubMed ID: 15654927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Algorithms for the pharmacotherapy of bipolar disorder.
    Motohashi N
    Psychiatry Clin Neurosci; 1999 Oct; 53 Suppl():S41-4. PubMed ID: 10560897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A common mechanism of action for three mood-stabilizing drugs.
    Williams RS; Cheng L; Mudge AW; Harwood AJ
    Nature; 2002 May; 417(6886):292-5. PubMed ID: 12015604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic treatment with both lithium and sodium valproate may normalize phosphoinositol cycle activity in bipolar patients.
    Silverstone PH; Wu RH; O'Donnell T; Ulrich M; Asghar SJ; Hanstock CC
    Hum Psychopharmacol; 2002 Oct; 17(7):321-7. PubMed ID: 12415549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug interactions of lithium and other antimanic/mood-stabilizing medications.
    Dunner DL
    J Clin Psychiatry; 2003; 64 Suppl 5():38-43. PubMed ID: 12720483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disodium valproate: new preparation. An alternative for acute mania after lithium failure or intolerance.
    Prescrire Int; 2001 Aug; 10(54):113-5. PubMed ID: 11718180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of anticonvulsants in the aftermath of mania.
    Cookson J; Elliott B
    J Psychopharmacol; 2006 Mar; 20(2 Suppl):23-30. PubMed ID: 16551669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The common inositol-reversible effect of mood stabilizers on neurons does not involve GSK3 inhibition, myo-inositol-1-phosphate synthase or the sodium-dependent myo-inositol transporters.
    Di Daniel E; Cheng L; Maycox PR; Mudge AW
    Mol Cell Neurosci; 2006; 32(1-2):27-36. PubMed ID: 16531065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycogen synthase kinase-3 is required for optimal de novo synthesis of inositol.
    Azab AN; He Q; Ju S; Li G; Greenberg ML
    Mol Microbiol; 2007 Feb; 63(4):1248-58. PubMed ID: 17257308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The association between carbamazepine and valproate and adverse cutaneous drug reactions in patients with bipolar disorder: a nested matched case-control study.
    Gau SS; Chao PF; Lin YJ; Chang CJ; Gau CS
    J Clin Psychopharmacol; 2008 Oct; 28(5):509-17. PubMed ID: 18794645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PtdIns(3,4,5)P(3) and inositol depletion as a cellular target of mood stabilizers.
    Teo R; King J; Dalton E; Ryves J; Williams RS; Harwood AJ
    Biochem Soc Trans; 2009 Oct; 37(Pt 5):1110-4. PubMed ID: 19754462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.